FARE Statements

FARE Statement on Department of Transportation Order

05/17/2019

FARE Statement on Public Comment to ICER Regarding Peanut Allergy Therapy Under Review

05/08/2019

Joint Statement on Impact of Shutdown on Therapy Review

01/17/2019

FARE Medical Advisors’ Letter to FDA on Epinephrine

08/15/2018

FARE Update on National Shortage of Epinephrine Auto-Injectors

08/09/2018

A Message from Lisa Gable: Update August 9, 2018

08/09/2018

A Message from Lisa Gable

08/03/2018

Food Allergy Research & Education Calls on FDA to Act Swiftly on Reported EpiPen Shortage

05/07/2018

FARE Letter to FDA

05/01/2018

Statement by Food Allergy Research & Education and Members of Clinical Advisory Board on Depiction of Food Allergies in Entertainment Media

02/13/2018

FARE Establishes Landmark Strategic Investment Fund

12/04/2017

FARE Statement on Congress’ Bipartisan Efforts to Stabilize the Healthcare System

10/18/2017

FARE Letter to Congress on Graham-Cassidy Bill

09/25/2017

FARE Statement on FDA Warning Letter

09/07/2017

Food Allergy Research & Education: New Data Shows Number of Anaphylactic Reactions Rising, Underscoring Critical Need for Food Allergy Therapies and Patient Education

08/17/2017

FARE Calls for Affordable Coverage of Chronic Conditions, Continued Caps on Patient Expenses

06/07/2017

A Statement from the CEO of FARE

09/07/2016

FARE Statement on Epinephrine Access and Price

08/24/2016

FARE Letter to NBC News Chairman Andrew Lack

05/12/2016

FARE Statement on Oral Immunotherapy for Food Allergies

02/18/2016